ALNY Alnylam Pharmaceuticals Inc

$ALNY This might see $125 before the end of the year. Questionable data, patent dispute on their largest product, no new products for years to come. I’m a fan of this company but until something changes, i don’t see a ton of upside right here.

$ALNY $1.4 Billion dollar invested in ALNY. Baillie Gifford's team have done their due diligence. This is as strong of an endorsement as we are going to see for a while. Get in 20% below their buy price.

$ALNY CEO recently signaled extremely bullish sentiment on ALNY stock, stating: It's a once-in-a-generation buy for anyone who's thinking of putting a few dollars into ..ALNY stock is sitting at a very good buying price… and as we deliver on our commitments, you can enjoy the ride up with us. Outperform target price $470

$ALNY there will not be any squeeze until fda approval in November that will trigger a pay out to alny

$ALNY looks like June 2024 gap on the weekly was mitigated. Will this be the turnaround point?

$ALNY it’s likely that the midterm result positively affected the direction of 340B reform, which influenced the ALNY board confidence on their future finance.

🔴 $ALNY 150P Nov 20 💰 $172,800 premium 💵 $0/contract 📊 2.6x Vol/OI 📍 Spot $163.59 💰 Large premium 🌊 Dark Flow | Options Flow

$ALNY breaking news: Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026 https://www.businesswire.com/news/home/20261103351345/en/Alnylam-to-Present-Five-Year-HELIOS-B-Data-and-Expanding-Evidence-on-the-Benefits-of-RNAi-Powered-TTR-Silencing-with-AMVUTTRA-vutrisiran-at-AHA-and-ISA-2026

$ALNY Q3 net income was 2.17 billion dollars on just 295.8 million dollars of pre-tax income. Note 14 in the 10-Q says Alnylam released 1.95 billion dollars of valuation allowance on prior-year deferred tax assets in the quarter, after concluding sustained profitability made them more likely than not to be realized. Not all of it got released though. Allowances are still held on some loss carryforwards and state research and development credits, where the filing expects future credit generation to exceed what can actually be used. Cash paid for taxes over the nine months was 29.8 million dollars.

$ALNY $NVO 🚨 TESTING INSTITUTIONAL BUY ZONE | Q3 EARNINGS NOV 4 🚨$NVO is stabilizing inside its $38.00 – $39.50 Institutional Buy Zone on the 8H chart! Wegovy/Ozempic demand holds strong into earnings. 📊 CHART ZONES ($NVO, 8H): • Smart Money Sell: $49.00 – $51.50 • Institutional Sell: $46.00 – $48.00 • Institutional Buy: $38.00 – $39.50 (LOAD ZONE) • Smart Money Buy: $36.50 – $37.80 • Flow: $68K split on 01/27 $40C @ Ask 🎯 KEY LEVELS: 🐂 Bull Trigger: Hold $38.00 & reclaim $41.50 to target $46+. 🐻 Bear Trigger: 8H close below $36.50. BIAS: Tactical Dip-Buy off $38–$39.50 Demand 📊📈#hovdid

ALNY Stock Hits Fresh 52-Week Low On Medicare Access Worries And Pipeline Delays $ALNY $VTI $VO https://stocktwits.com/news/equity/markets/alny-stock-hits-fresh-52-week-low-on-medicare-access-worries-and-pipeline-delays/cZUQHVwR9R7

$ALNY reported earnings before the open: adjusted EPS of $16.26 vs. $1.66 estimated, a beat of 879.5%. I used Stock Meadow to review the results.

$ALNY Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $16.26 up 409.72% YoY • Reported revenue of $1.46B up 16.74% YoY • Alnylam targets, through its Alnylam 2030 strategy, 25%+ total revenue compound annual growth rate and approximately 30% non-GAAP operating margin through year-end 2030, while investing approximately 30% of revenues in non-GAAP R&D.

$ALNY This is positive news. Buyback should light the match to a rebound. We are so undervalued.

$ALNY So tax loss harvesting exacerbating this already painful selloff? Green all around save for here.

Sixty percent down on the year and $ALNY still has a November clock ticking imo Q3 was a sales story, not a science story. Amvuttra did 1.13 billion, up 65% year over year, and the stock still got smoked 25% in a day on slower patient starts and a 340B reimbursement cloud meanwhile cemdisiran decides this month. Priority Review, the first siRNA up for approval in myasthenia gravis, one shot every 12 weeks, and Regeneron runs the filing while Alnylam banks royalties up to 15% Barclays cut its target to 380 from 450 on Monday. after the move, obviously near 158 today, right on the 52 week low near 156. the pipeline did not break, the price did

Alnylam $ALNY will present five-year HELIOS-B data on AMVUTTRA at AHA. Nov 9 at 10:40 a.m. ET, a post hoc analysis at 10:50, then ISA on Nov 16-18. Shares closed at $158.00 on Monday, below the SMA50 and below the SMA200, RSI 21 (oversold). More details in our hub. Not investment advice.

$ALNY RNAi seems to be especially advantageous for targeting mutant genes that cause abnormal protein aggregates, for example in the Huntington’s.

$ALNY 🚨 TESTING MULTI-YEAR DEMAND | RNAi PIPELINE VS COMMERCIAL SHAKEOUT 🚨A heavy post-earnings drop driven by Amvuttra guidance trims has flushed $ALNY directly into the $150.00 – $165.00 Institutional Buy Zone on the weekly chart! RNAi technology lead remains strong while price retests major multi-year trendline support. 📊 CHART ZONES ($ALNY, 1W): • Smart Money Sell Zone: $265.00 – $280.00 • Institutional Resistance Target: $225.00 – $240.00 • Institutional Buy Zone: $150.00 – $165.00 (CURRENT SUPPORT) • Smart Money Buy Zone: $115.00 – $130.00 🎯 KEY LEVELS TO CONFIRM: 🐂 Bull Trigger: Defend $150.00 support & push past $185.00 to confirm relief path toward $225+. 🐻 Bear Trigger: Break below $150.00 risks a deeper drop to the $115 – $130 Smart Money Buy Zone. BIAS: Tactical Bounce Setup off $150–$165 Demand Floor 📊📈#hovdid

$ALNY watch this explode next week when all the tech and AI money start pouring into healthcare stocks.